Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 9/2022

26.07.2022 | Chronic Daily Headache (S-J Wang, Section Editor)

CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache

verfasst von: Shu-Ting Chen, Jr-Wei Wu

Erschienen in: Current Pain and Headache Reports | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Chronic cluster headache (CH) substantially affects patients’ quality of life, and treatment remains challenging. The current article reviewed controlled studies for new treatment options targeting calcitonin gene–related peptide (CGRP) or its receptors in CH and discussed the current gaps and future directions for the treatment of chronic CH.

Recent Findings

Two anti-CGRP monoclonal antibodies (i.e., galcanezumab and fremanezumab) completed randomized-control trials for efficacy for the preventive treatment of episodic and chronic CH. Galcanezumab was effective for preventing episodic CH but not chronic CH. Fremanezumab was ineffective in preventing episodic and chronic CH. Studies for other anti-CGRP monoclonal antibodies and CGRP antagonists are still pending for results.

Summary

There are no randomized controlled trials for CGRP-targeted therapies that showed efficacy for chronic CH prevention. The different responses to galcanezumab between episodic and chronic CH may be due to the study design, i.e., the allowance of concomitant preventive therapies in the chronic CH study but not in the episodic CH study. Another reason for the discrepancies is the different roles and sensitivity of CGRP in chronic CH.
Literatur
1.
• May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ. Cluster headache. Nat Rev Dis Primers. 2018;4:18006. 1. This article provides a comprehensive review of the clinical presentations, pathophysiology, and treatments for cluster headache.
2.
Schurks M, Kurth T, de Jesus J, Jonjic M, Rosskopf D, Diener HC. Cluster headache: clinical presentation, lifestyle features, and medical treatment. Headache. 2006;46:1246–54.PubMedCrossRef
3.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
4.
5.
Donnet A, Lanteri-Minet M, Guegan-Massardier E, Mick G, Fabre N, Géraud G, et al. Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry. 2007;78:1354–8.PubMedPubMedCentralCrossRef
6.
Manzoni GC, Micieli G, Granella F, Tassorelli C, Zanferrari C, Cavallini A. Cluster headache—course over ten years in 189 patients. Cephalalgia. 1991;11:169–74.PubMedCrossRef
7.
Ko C-A, Lin G-Y, Ting C-H, Sung Y-F, Lee J-T, Tsai C-K, et al. Clinical features of cluster headache: a hospital-based study in Taiwan. Front Neurol. 2021;12.
8.
Lin KH, Wang PJ, Fuh JL, Lu SR, Chung CT, Tsou HK, et al. Cluster headache in the Taiwanese — a clinic-based study. Cephalalgia. 2004;24:631–8.PubMedCrossRef
9.
Imai N, Yagi N, Kuroda R, Konishi T, Serizawa M, Kobari M. Clinical profile of cluster headaches in Japan: low prevalence of chronic cluster headache, and uncoupling of sense and behaviour of restlessness. Cephalalgia. 2011;31:628–33.PubMedCrossRef
10.
11.
Obermann M, Nägel S, Ose C, Sonuc N, Scherag A, Storch P, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol. 2021;20:29–37.PubMedCrossRef
12.
Mitsikostas DD, Edvinsson L, Jensen RH, Katsarava Z, Lampl C, Negro A, et al. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:79.PubMedPubMedCentralCrossRef
13.
Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl 2):20–32.PubMedCrossRef
14.
Cohen F, Yuan H, Silberstein SD. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022.
15.
Yang F-C, Chou K-H, Fuh J-L, Lee P-L, Lirng J-F, Lin Y-Y, et al. Altered hypothalamic functional connectivity in cluster headache: a longitudinal resting-state functional MRI study. J Neurol Neurosurg Psychiatry. 2015;86(4):437–45.PubMedCrossRef
16.
17.
Barloese MC. Neurobiology and sleep disorders in cluster headache. J Headache Pain. 2015;16:562.PubMedCrossRef
18.
Buture A, Boland JW, Dikomitis L, Ahmed F. Update on the pathophysiology of cluster headache: imaging and neuropeptide studies. J Pain Res. 2019;12:269–81.PubMedPubMedCentralCrossRef
19.
Sprenger T, Ruether KV, Boecker H, Valet M, Berthele A, Pfaffenrath V, et al. Altered metabolism in frontal brain circuits in cluster headache. Cephalalgia. 2007;27:1033–42.PubMedCrossRef
20.
Yang FC, Chou KH, Fuh JL, Huang CC, Lirng JF, Lin YY, et al. Altered gray matter volume in the frontal pain modulation network in patients with cluster headache. Pain. 2013;154:801–7.PubMedCrossRef
21.
Goadsby PJ. Cluster headache and the trigeminal-autonomic reflex: Driving or being driven? Cephalalgia. 2018;38:1415–7.PubMedCrossRef
22.
Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622–651.
23.
Edvinsson L, Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia. 2008;28:1245–58.PubMedCrossRef
24.
Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60:119–23.PubMedCrossRef
25.
Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427–434.
26.
Kamm K, Straube A, Ruscheweyh R. Baseline tear fluid CGRP is elevated in active cluster headache patients as long as they have not taken attack abortive medication. Cephalalgia. 2021;41:69–77.PubMedCrossRef
27.
Tuka B, Szabó N, Tóth E, Kincses ZT, Párdutz Á, Szok D, et al. Release of PACAP-38 in episodic cluster headache patients — an exploratory study. J Headache Pain. 2016;17:69–69.PubMedPubMedCentralCrossRef
28.
Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(Pt 3):427–434.
29.
30.
31.
• Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75:1187–1197. This infusion study found CGRP infusion less commonly triggered CH attacks in chronic (50%) than episodic cluster headache patients (89%), suggesting differences in CGRP sensitivity between episodic and chronic cluster headache patients.
32.
Snoer A, Vollesen ALH, Beske RP, Guo S, Hoffmann J, Fahrenkrug J, et al. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019;39:575–84.PubMedCrossRef
33.
Vollesen ALH, Snoer A, Chaudhry B, Petersen AS, Hagedorn A, Hoffmann J, et al. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia. 2020;40:1474–88.PubMedCrossRef
34.
Pellesi L, Chaudhry BA, Vollesen ALH, Snoer AH, Baumann K, Skov PS, et al. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia. 0:03331024211056248.
35.
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–54.PubMedCrossRef
36.
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080–8.PubMedPubMedCentralCrossRef
37.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study. 2018;91:e2211–21.
38.
• Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132–141. This manuscript demonstrates the efficacy of galcanezumab for the preventive treatment of episodic cluster headache.
39.
Plato B, Andrews JS, Rettiganti M, Tockhorn-Heidenreich A, Bardos J, Wenzel R, et al. Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure. Cephalalgia Reports. 2021;4:25158163211015656.CrossRef
40.
• Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40:935–948. This paper found that galcanezumab is ineffective for the preventive treatment of chronic cluster headaches.
41.
Lanteri-Minet M, Kalidas K, Oakes TM, Bardos J, Zhou C, Wenzel R, et al. Acute and preventive treatment use in a phase 3 randomized trial of galcanezumab in chronic cluster headache (4023). Neurology. 2020;94:4023.
42.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999–2008.PubMedCrossRef
43.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.PubMedCrossRef
44.
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–40.PubMedCrossRef
45.
• Lipton RB, Diener HC, Barbanti P, Schiemann J, Barash S, Cohen JM, et al. Efficacy and safety of fremanezumab for the prevention of episodic cluster headache: results of a randomized, double-blind, placebo controlled, phase 3 study. Cephalalgia. 2019;39:358–9. This abstract from the Internation Headache Congress 2019 showed that fremanezumab is ineffective for the preventive treatment of episodic cluster headache.
46.
Chan C, Goadsby PJ. CGRP pathway monoclonal antibodies for cluster headache. Expert Opin Biol Ther. 2020;20:947–53.PubMedCrossRef
47.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–32.PubMedCrossRef
48.
Wang SJ, Roxas AA Jr, Saravia B, Kim BK, Chowdhury D, Riachi N, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia. 2021;41:1285–97.PubMedPubMedCentralCrossRef
49.
Silvestro M, Tessitore A. Scotto di Clemente F, Tedeschi G, Russo A: Erenumab Efficacy on comorbid cluster headache in patients with migraine: a real-world case series. Headache. 2020;60:1187–95.PubMedCrossRef
50.
Riederer F, Wenner AM. Erenumab for chronic cluster headache: a case report. Cephalalgia Reports. 2020;3:2515816320947713.CrossRef
51.
Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241–54.PubMedPubMedCentralCrossRef
52.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365–77.PubMedPubMedCentralCrossRef
53.
Ruscheweyh R, Broessner G, Goßrau G, Heinze-Kuhn K, Jürgens TP, Kaltseis K, et al. Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia. 2020;40:1574–84.PubMedPubMedCentralCrossRef
54.
Tepper D. Gepants. Headache: J Head Face Pain. 2020;60:1037–1039.
55.
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials. ACHIEVE I and II Headache. 2020;60:686–700.PubMed
56.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737–45.PubMedCrossRef
57.
58.
Slomski A. Oral Rimegepant Safe, Effective for migraine prevention. JAMA. 2021;325:713–713.PubMed
59.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706.PubMedCrossRef
60.
Lipton RB, Micieli G, Russell D, Solomon S, Tfelt-Hansen P, Waldenlind E. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia. 1995;15:452–62.PubMedCrossRef
61.
Dodick DW, Goadsby PJ, Ashina M, Tassorelli C, Hundemer HP, Bardos JN, et al. Challenges and complexities in designing cluster headache prevention clinical trials: a narrative review. Headache. 2022;62:453–72.PubMedPubMedCentralCrossRef
62.
Bussone G, Leone M, Peccarisi C, Micieli G, Granella F, Magri M, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30:411–7.PubMedCrossRef
63.
Steiner TJ, Hering R, Couturier EG, Davies PT, Whitmarsh TE. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia. 1997;17:673–5.PubMedCrossRef
64.
Barloese MCJ, Beske RP, Petersen AS, Haddock B, Lund N, Jensen RH. Episodic and chronic cluster headache: differences in family history, traumatic head injury, and chronorisk. Headache. 2020;60:515–25.PubMedCrossRef
65.
Barloese M, Haddock B, Lund NT, Petersen A, Jensen R. Chronorisk in cluster headache: a tool for individualised therapy? Cephalalgia. 2018;38:2058–67.PubMedCrossRef
66.
Naegel S, Holle D, Obermann M. Structural imaging in cluster headache. Curr Pain Headache Rep. 2014;18:415.PubMedCrossRef
67.
Rustichelli C, Lo Castro F, Baraldi C, Ferrari A. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. Expert Opin Investig Drugs. 2020;29:1269–75.PubMedCrossRef
Metadaten
Titel
CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache
verfasst von
Shu-Ting Chen
Jr-Wei Wu
Publikationsdatum
26.07.2022
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 9/2022
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-022-01070-6

Weitere Artikel der Ausgabe 9/2022

Current Pain and Headache Reports 9/2022 Zur Ausgabe

Chronic Pain Medicine (O Viswanath, Section Editor)

Post-thoracotomy Pain Syndrome

Acute Pain Medicine (R Urman, Section Editor)

Psychiatric Comorbidities Associated with Persistent Postoperative Opioid Use

Neuropathic Pain (A Abd-Elsayed, Section Editor)

Infusion Therapy in the Treatment of Neuropathic Pain

Chronic Pain Medicine (O Viswanath, Section Editor)

Interventional Treatment Modalities for Chronic Abdominal and Pelvic Visceral Pain

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren